Allegro Biotech
Liège
About Allegro Biotech
Allegro was founded in 2021 with the ultimate vision to augment humanity and prolong life, engineering the body atom-by-atom, blending nanotech and biotech. The company developed a promising nanotechnology platform to build therapeutic nanoparticles for orthopaedics, neuroscience, and chronic degenerative diseases. Allegro brings Xyletra to the market, the world's first disease-modifying treatment for osteoarthritis, which stops the degenerative process and alleviates pain with a year-long effect on a single shot administration.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Total funding: $10.1M
- Funding stage: Seed
- Last round: Seed (Jul 2025)
- Website: allegro.bio
- Phone: [email protected]
Industries & Categories
Biotechnology, Life Science, Medical, Nanotechnology, Neuroscience
Social Profiles
Canonical: https://fsome.com/organization/allegro-biotech-38695 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.